John Mendlein

John Mendlein, Ph.D. is an Executive Partner at Flagship Pioneering and longtime member of Flagship’s broader ecosystem of companies. He is a highly experienced biotech leader and has served in numerous executive and board roles. John is co-author or co-inventor of over 210 publications and published patents. He has served on the boards of the Biotechnology Innovation Organization (BIO), as well as on Moderna (NASDAQ: MRNA), Axcella Health and Editas Medicine (NASDAQ: EDIT). John currently serves as the Chairman of the Board of Directors at Kintai Therapeutics and board member of Cogen Immune Medicine and Ohana Biosciences.

John holds a Ph.D. in physiology and biophysics from the University of California, Los Angeles, a J.D. from the University of California, Hastings College of the Law, and a B.S. in biology from the University of Miami.